Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451714 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL5280142 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL31362880 | 0.77 | KDM4E (0.37) | — | |
| SCHEMBL9642490 | 0.75 | — | — | |
| SCHEMBL2525941 | 0.75 | — | — | |
| SCHEMBL23903753 | 0.73 | GLRA1 (0.35) | — | |
| SCHEMBL18822178 | 0.73 | — | — | |
| SCHEMBL10037275 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL16668584 | 0.73 | KDM4E (0.34) | — | |
| Hydrochloric Acid SCHEMBL16668503 | 0.73 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739680-A1 | SOLID FORMS OF TRPV4 ANTAGONISTS | Actio Biosciences, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250333403-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12391683-B2 | Therapeutic compounds and methods | ACTIO BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4551572-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Actio Biosciences, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025014818-A1 | SOLID FORMS OF GSK2798745, A TRPV4 ANTAGONIST | ACTIO BIOSCIENCES, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240287055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11987577-B2 | Therapeutic compounds and methods | ACTIO BIOSCIENCES, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240076294-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117447466-A | Oxazole compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-01-26 | — | — | CN | disclosed |
| WO-2024011214-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20030171364-A1 | Novel substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them | BURNOUF CATHERINE (FR) | 2003-09-11 | — | — | US | disclosed |
| CN-1433415-A | N-[5-[[[5-alkyl-2-oxazlyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | CN | disclosed |
| CN-1433416-A | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamideinhibitors of cyclin dependent kinases | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6515004-B1 | Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| EP-1240166-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240165-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]-CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | Bristol-Myers Squibb Company (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044242-A9 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001044242-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044241-A1 | N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]-CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6214852-B1 | ANTIPROLIFERATIVE AGENTS; TREATMENT OF CANCER, INFLAMMATION, AND ARTHRITIS | BRISTOL-MYERS SQUIBB COMPANY | 2001-04-10 | — | — | US | disclosed |